Gaithersburg-based MedImmune Inc. announced yesterday that it has completed enrolling patients for its late-stage clinical trial to test the effectiveness and safety of a treatment it is developing for the prevention of a leading cause of pneumonia and bronchitis in infants and small children, respiratory syncytial virus disease, or RSV.
The biotechnology company said it has enrolled 1,503 patients for the clinical trial.
The trial is being conducted at 139 medical centers in the United States, Canada and Britain to evaluate the treatment, called MEDI-493. The drug is what is known as a monoclonal antibody, which binds to the surface of the virus and prevents it from infecting cells.
In early studies, the company said, MEDI-493 was shown to neutralize the virus and to reduce infection.
The trial is expected to be completed in May.
MEDI-493 is administered by injection and, if successfully developed, the company said, might be easier to use than MedImmune's first generation product for RSV, called RespiGam, administered through intravenous infusion. That process can take up to four hours.
Pub Date: 12/17/96